For clinical trial design, it will be relevant to note that all neuroprotective treatment trials in MS which had failed on these primary outcome measures, now retrospectively showed significant effects regarding Nf levels (Preziosa et al., 2020). The gene discussed is NFASC; the disease is myeloid sarcoma.